Thermo Fisher Scientific
Life sciences company providing analytical instruments, equipment, reagents, consumables, software and services for research, manufacturing, analysis, discovery and diagnostics
What the page says before deeper research
Quality, growth, value, ownership, risk, and source confidence.
Moat 95/100 with low retention risk.
Growth appears mixed from +5.4% YoY revenue growth.
Forward P/E of 18.3x versus +5.4% growth gives a 3.4x multiple-to-growth read.
No SEC-backed 13F layer is matched yet, so ownership confirmation is unavailable.
Monitor valuation, retention, and AI disruption risk.
Fundamentals from finnhub as of 2026-05-17; ownership confirmation is not available here.
Revenue growth shows whether Thermo Fisher’s lab and diagnostics franchise is still expanding.
Beginner valuation check
Data pending from FMP or Finnhub.
Positive price performance shows recent market sentiment, not a full investment thesis.
Forward P/E around 18.3x means investors pay about $18.3 for each expected $1 of future profit per share, usually the next 12 months or next fiscal year. It is a forecast, not a fact.
A P/E around 23.8x means investors pay about $23.8 for each $1 the company earned per share over the last 12 months, usually the last four quarterly reports.
Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.
Beginner guide
Thermo Fisher makes scientific instruments and supplies that help scientists in labs do experiments, test medicines, and study DNA.
Life sciences company providing analytical instruments, equipment, reagents, consumables, software and services for research, manufacturing, analysis, discovery and diagnostics
Thermo Fisher Scientific makes money through Life Sciences Solutions (~22% of revenue), Analytical Instruments (~16% of revenue), Specialty Diagnostics (~15% of revenue), and Laboratory Products & Biopharma (~40% of revenue).
Mission-critical scientific workflows create 98%+ customer retention
Thermo Fisher Scientific can disappoint if execution, competition, valuation, or demand cycles weaken growth, margins, customer retention, or investor confidence.
Thermo Fisher Scientific is like a specialized business engine: investors want to know whether life sciences solutions can keep producing durable cash flow.
You are basically betting that Thermo Fisher Scientific can keep turning life sciences solutions into durable value while managing execution, competition, valuation, or demand cycles.
A 0-100 shortcut for how defensible the business looks in this company brief. Thermo Fisher Scientific is scored at 95.
How painful it is for customers to leave. this company brief rates Thermo Fisher Scientific as high.
Whether existing customers tend to spend more or less over time. The company brief model uses 108%.
The main pieces of the company here are Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma.
Price divided by earnings. It is a quick valuation check, but it can mislead when earnings are temporarily high, low, or negative.
A quarterly filing that shows what many large institutional investors owned at quarter end.
The first four questions
Thermo Fisher’s mission-critical scientific workflows support high customer retention, and the company’s life sciences solutions stack is the clearest operating engine to watch.
TMO can disappoint if execution, competition, valuation, or demand cycles weaken growth, customer retention, or confidence in the lab spending cycle.
Life Sciences Solutions
Next earnings date unavailable from configured sources.
Bull / Neutral / Bear
You are basically betting that Thermo Fisher Scientific can keep turning its lab workflow footprint into durable value while the market weighs growth against an 18.3x forward P/E.
Forward P/E around 18.3x remains in line with the company’s growth profile and operating stability.
Mission-critical scientific workflows keep customer relationships sticky and support steady demand across life sciences solutions, instruments, diagnostics, and lab products.
Life Sciences Solutions stays resilient while revenue growth remains positive around +5.4% or better.
You are basically betting that Thermo Fisher Scientific can keep turning its lab workflow footprint into durable value while the market weighs growth against an 18.3x forward P/E.
Forward P/E around 18.3x remains in line with the company’s growth profile and operating stability.
TMO can disappoint if demand, execution, or competitive pressure weakens the lab workflow engine and investors start questioning the durability of its scientific consumables and instrument ecosystem.
Revenue growth cools, the lab-products engine softens, or ownership flow remains absent from SEC-backed 13F data.
Beginner checklist
Needs earnings calendar data from a provider.
Revenue growth shows whether Thermo Fisher’s lab and diagnostics franchise is still expanding.
Margin trend needs company financial statement data; do not infer it from price movement.
Forward P/E is the cleanest beginner valuation anchor available in this dataset.
No SEC-backed ownership rows are available for this ticker yet.
Needs insider transaction data from a provider.
For TMO, start with whether Life Sciences Solutions is strengthening or slowing.
Thermo Fisher Scientific is exposure to life sciences tools & services operating model with high switching costs and 108% net revenue retention.
Mission-critical scientific workflows create 98%+ customer retention
The main question is whether the company can keep customer value compounding without margin pressure eroding the moat.
Pro access unlocks the workflow simulator for this company brief.
Simulator coverage pending
This ticker has a company brief, but richer workflow modules have not been built yet.
No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.
- Mission-critical scientific workflows create 98%+ customer retention
- Regulatory validation requirements make switching extremely costly (6-18 months)
- Proprietary instrument data formats lock customers into TMO's software ecosystem
- 15+ year instrument lifecycles with mandatory software updates drive recurring revenue
- Deep integration with lab operations makes TMO's software essential daily infrastructure